JP2008505636A - Ｈｃｖに有効なｃｔｌ反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途 - Google Patents

Ｈｃｖに有効なｃｔｌ反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途 Download PDF

Info

Publication number
JP2008505636A
JP2008505636A JP2007520225A JP2007520225A JP2008505636A JP 2008505636 A JP2008505636 A JP 2008505636A JP 2007520225 A JP2007520225 A JP 2007520225A JP 2007520225 A JP2007520225 A JP 2007520225A JP 2008505636 A JP2008505636 A JP 2008505636A
Authority
JP
Japan
Prior art keywords
epitope
hcv
supertype
cells
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007520225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008505636A5 (enExample
Inventor
ファン・ユキョン
キム・ナムキュン
パク・ジュンミン
リム・オクジェ
パク・マーンフン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mogam Institute for Biomedical Research
Original Assignee
Mogam Institute for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mogam Institute for Biomedical Research filed Critical Mogam Institute for Biomedical Research
Publication of JP2008505636A publication Critical patent/JP2008505636A/ja
Publication of JP2008505636A5 publication Critical patent/JP2008505636A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007520225A 2004-07-03 2005-07-04 Ｈｃｖに有効なｃｔｌ反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途 Pending JP2008505636A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20040051782 2004-07-03
PCT/KR2005/002111 WO2006004362A1 (en) 2004-07-03 2005-07-04 Supertype epitopes, oligonucleotides coding the same which induce effective ctl response against hcv and the use thereof

Publications (2)

Publication Number Publication Date
JP2008505636A true JP2008505636A (ja) 2008-02-28
JP2008505636A5 JP2008505636A5 (enExample) 2008-07-31

Family

ID=35783125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007520225A Pending JP2008505636A (ja) 2004-07-03 2005-07-04 Ｈｃｖに有効なｃｔｌ反応を誘導するスーパータイプのエピトープ、これをコードするオリゴヌクレオチド並びにそれらの用途

Country Status (6)

Country Link
US (1) US20080112977A1 (enExample)
EP (1) EP1778719A1 (enExample)
JP (1) JP2008505636A (enExample)
KR (1) KR100790646B1 (enExample)
CN (1) CN1976946A (enExample)
WO (1) WO2006004362A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101294514B1 (ko) * 2007-09-18 2013-08-12 가부시키가이샤 그린 펩티드 Ｃｔｌ 유도제 조성물
CN102174522B (zh) * 2011-02-24 2013-11-06 杭州师范大学 一种4-1bbl蛋白的制备方法
WO2016079143A1 (de) 2014-11-17 2016-05-26 Pharis Biotec Gmbh Inhibitor der viralen hepatitis c infektion
CN107827959B (zh) * 2017-11-09 2018-10-30 杭州续缓生物科技有限公司 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507525A (ja) * 1993-03-05 1996-08-13 サイテル コーポレイション Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
JP2002531133A (ja) * 1998-12-09 2002-09-24 アメリカ合衆国 複数の共刺激分子を発現する組換えベクターおよびその利用
JP2003528924A (ja) * 2000-03-31 2003-09-30 パーデュー・リサーチ・ファウンデイション リガンド免疫原複合体を用いる処置方法
WO2003090687A2 (en) * 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to increase immune response

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6297048B1 (en) * 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
ES2197170T3 (es) * 1993-11-04 2004-01-01 Innogenetics N.V. Epitopos de celulas t humanas inmunologicamente dominantes del virus de la hepatitis c.
US6235888B1 (en) * 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
AU5776799A (en) * 1998-08-21 2000-03-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Modified hcv peptide vaccines
ES2411096T3 (es) * 1999-10-27 2013-07-04 Novartis Vaccines And Diagnostics, Inc. Activación de linfocitos T específicos contra el VHC
JP2003064096A (ja) 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Ｃ型肝炎ウイルス特異的細胞障害性ｔ細胞認識エピトープ

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08507525A (ja) * 1993-03-05 1996-08-13 サイテル コーポレイション Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
JP2002531133A (ja) * 1998-12-09 2002-09-24 アメリカ合衆国 複数の共刺激分子を発現する組換えベクターおよびその利用
JP2003528924A (ja) * 2000-03-31 2003-09-30 パーデュー・リサーチ・ファウンデイション リガンド免疫原複合体を用いる処置方法
WO2003090687A2 (en) * 2002-04-25 2003-11-06 University Of Connecticut Health Center Using heat shock proteins to increase immune response

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHINESE JOURNAL OF BIOTECHNOLOGY, vol. 19, no. 2, JPN6010013811, 2003, pages 158 - 162, ISSN: 0001565174 *
HEPATOLOGY, vol. Vol.38, No.4, Suppl.1, JPN6010013813, 2003, pages 185 - 62, ISSN: 0001565173 *
JOURNAL OF HEPATOLOGY, vol. Vol.36, Supplement 1, JPN6010013815, 2002, pages 5 - 9, ISSN: 0001565172 *
JOURNAL OF IMMUNOLOGY, vol. 161, JPN6010013808, 1998, pages 4563 - 4571, ISSN: 0001565175 *
JOURNAL OF IMMUNOLOGY, vol. 162, JPN6010013804, 1999, pages 1156 - 1164, ISSN: 0001565176 *

Also Published As

Publication number Publication date
EP1778719A1 (en) 2007-05-02
US20080112977A1 (en) 2008-05-15
CN1976946A (zh) 2007-06-06
WO2006004362A1 (en) 2006-01-12
KR20060049824A (ko) 2006-05-19
KR100790646B1 (ko) 2008-01-02

Similar Documents

Publication Publication Date Title
Rehermann et al. Cell mediated immune response to the hepatitis C virus
Sarobe et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2. 1 binding positions.
US20100099613A1 (en) Peptides for inducing a ctl and/or htl response to hepatitis c virus
Racanelli et al. Hepatitis C virus infection: when silence is deception
JP2003510099A (ja) ペプチドおよび核酸組成物を使用する、ヒト免疫不全ウイルス−１に対する細胞性免疫応答の誘導
JP2004512814A (ja) ペプチドおよび核酸組成物を使用する、ヒトパピローマウイルスに対する細胞性免疫応答の誘導
JP2003509465A (ja) ペプチドおよび核酸組成物を使用する、ｃ型肝炎ウイルスに対する細胞性免疫応答の誘導
JP2003530083A (ja) ペプチドおよび核酸組成物を使用する、ＨＥＲ２／ｎｅｕに対する細胞性免疫応答の誘導
van der Most et al. Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice
Pancholi et al. DNA prime-canarypox boost with polycistronic hepatitis C virus (HCV) genes generates potent immune responses to HCV structural and nonstructural proteins
Zingaretti et al. Why is it so difficult to develop a hepatitis C virus preventive vaccine?
Wedemeyer et al. Oral immunization with HCV-NS3—transformed Salmonella: Induction of HCV-specific CTL in a transgenic mouse model
JP2017518051A (ja) Ｂ型肝炎ウイルス感染に対する治療ワクチン接種のための合成長鎖ペプチド（ｓｌｐ）
Urbani et al. Identification of immunodominant hepatitis C virus (HCV)‐specific cytotoxic T‐cell epitopes by stimulation with endogenously synthesized HCV antigens
Himoudi et al. Comparative vaccine studies in HLA-A2. 1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection
US20140105925A1 (en) Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Dengue Virus Infection
US7785875B2 (en) Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
Shata et al. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees
Kuzushita et al. Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens
Hartoonian et al. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine
Mizukoshi et al. Immune responses and immunity in hepatitis C virus infection.
Torresi et al. Neutralising antibody, CTL and dendritic cell responses to hepatitis C virus: a preventative vaccine strategy
Mekonnen et al. Enhanced T cell responses induced by a necrotic dendritic cell vaccine, expressing HCV NS3
Zeng et al. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice
KR100790646B1 (ko) 세포매개 면역반응을 효과적으로 유도하는 ｈｃｖ수퍼타입 에피토프, 그를 코딩하는 올리고뉴클레오타이드및 그의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100810